<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024813</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21845</org_study_id>
    <secondary_id>2019-001760-30</secondary_id>
    <nct_id>NCT04024813</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC</brief_title>
  <official_title>A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the effect of seladelpar treatment compared to&#xD;
      placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis&#xD;
      (PSC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Actual">January 9, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Dose masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change in Baseline serum alkaline phosphatase (AP) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs), as well as biochemistry, hematology, and urinalysis</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of PSC-related symptoms or procedures</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hepatic disease progression events, defined by the occurrence of liver transplantation, MELD score, hepatic decompensation events, and/or hepatocellular carcinoma</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Placebo (N=25)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for the remainder of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar 5 mg (N=25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg seladelpar daily for the remainder of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar 10 mg (N=25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg seladelpar for the remainder of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladepar 25 mg (N=25)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg seladelpar for the remainder of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seladelpar</intervention_name>
    <description>Capsule(s) administered orally once daily</description>
    <arm_group_label>Seladelpar 10 mg (N=25)</arm_group_label>
    <arm_group_label>Seladelpar 5 mg (N=25)</arm_group_label>
    <arm_group_label>Seladepar 25 mg (N=25)</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match Seladelpar</intervention_name>
    <description>Capsule(s) administered orally once daily</description>
    <arm_group_label>Placebo (N=25)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of PSC based on any two of the following three criteria:&#xD;
&#xD;
               -  Historical evidence of an elevated AP &gt; ULN from any prior laboratory result&#xD;
&#xD;
               -  Liver biopsy consistent with PSC&#xD;
&#xD;
               -  Abnormal cholangiography consistent with PSC as measured by MRCP, ERCP, or&#xD;
                  percutaneous transhepatic cholangiography (PTC)&#xD;
&#xD;
          2. Subjects must have the following specific additional laboratory parameters measured by&#xD;
             the Central Laboratory at Screening:&#xD;
&#xD;
               -  AP ≥ 1.5 × ULN and &lt; 8 × ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 2 × ULN&#xD;
&#xD;
               -  ALT and AST ≤ 5 × ULN&#xD;
&#xD;
               -  eGFR &gt; 60 mL/min/1.73 m^2&#xD;
&#xD;
               -  Platelets ≥ 140 × 10^3/µL&#xD;
&#xD;
               -  International Normalized Ratio (INR) ≤ 1.3 (in the absence of warfarin or other&#xD;
                  anticoagulant therapy)&#xD;
&#xD;
               -  Albumin ≥ 3.5 g/dL&#xD;
&#xD;
          3. Patients taking UDCA will be allowed to enroll if meeting the following criteria:&#xD;
&#xD;
               -  Total daily dose of ≤ 20 mg/kg/day&#xD;
&#xD;
               -  A minimum of 6 months of stable treatment&#xD;
&#xD;
               -  Minimum of 12 weeks off treatment prior to Screening if UDCA is recently&#xD;
                  discontinued&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant acute or chronic liver disease of an etiology other than PSC&#xD;
&#xD;
          2. Patients with a diagnosis of overlapping autoimmune hepatitis (AIH) and PSC&#xD;
&#xD;
          3. Secondary or IgG4 related sclerosing cholangitis&#xD;
&#xD;
          4. Small duct PSC&#xD;
&#xD;
          5. Presence of a cholangiocarcinoma on cholangiography or MRI at Screening as determined&#xD;
             by the central radiologist and the principal investigator (PI) or medical monitor&#xD;
&#xD;
          6. Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation&#xD;
             procedure of a stricture within 12 weeks of Screening&#xD;
&#xD;
          7. History, evidence, or high suspicion of cholangiocarcinoma or other hepatobiliary&#xD;
             malignancy based on imaging, screening laboratory values, and/or clinical symptoms&#xD;
&#xD;
          8. Presumptive or diagnosed acute cholangitis within 12 weeks of Screening and through&#xD;
             Day 1&#xD;
&#xD;
          9. Evidence of compensated or decompensated cirrhosis based on histology, relevant&#xD;
             medical complications, or laboratory parameters:&#xD;
&#xD;
               -  Historical liver biopsy demonstrating cirrhosis (eg, Ludwig Stage 4 or Ishak&#xD;
                  Stage 5)&#xD;
&#xD;
               -  Current or prior history of decompensated liver disease, including ascites,&#xD;
                  hepatic encephalopathy, variceal bleeding or other clinical conditions consistent&#xD;
                  with cirrhosis and/or portal hypertension,&#xD;
&#xD;
               -  Liver stiffness &gt; 14.4 kPa by FibroScan, or&#xD;
&#xD;
               -  Combined low platelet count (&lt; 140 × 10^3/µL ) with one of the following:&#xD;
&#xD;
                    -  Serum albumin &lt; 3.5 g/dL,&#xD;
&#xD;
                    -  INR &gt; 1.3 (not due to antithrombotic agent use), or&#xD;
&#xD;
                    -  Total bilirubin &gt; ULN&#xD;
&#xD;
         10. Prior or actively listed for liver transplantation&#xD;
&#xD;
         11. Prior exposure to seladelpar&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sutter Pacific Medical Foundation - California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver and Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Centre for Liver Disease-Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Mysłowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSC</keyword>
  <keyword>Cholangitis, Sclerosing</keyword>
  <keyword>Cholangitis</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seladelpar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

